|Mr. Remi Barbier||Founder, Chairman, CEO & Pres||881.99k||N/A||1960|
|Mr. Eric J. Schoen||Chief Financial Officer||181.75k||N/A||1968|
|Dr. Nadav Friedmann||COO, Chief Medical Officer & Director||320k||N/A||1943|
|Dr. George Thornton||Sr. VP of Technology||N/A||N/A||N/A|
|Mr. Michael Zamloot||Sr. VP of Technical Operations||N/A||N/A||N/A|
Cassava Sciences, Inc., a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.
Cassava Sciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.